The patient received treatment with crizotinib and entrectinib successively. No new severe drug-related adverse events were observed. This case suggests that in patients with ROS1 fusion-positive nonsmall cell lung cancer who have experienced prior ROS1-tyrosine kinase inhibitor treatment failure and concomitant severe renal insufficiency, repotrectinib may represent a potential and tolerable treatment option when fully assessing clinical risks and ensuring close monitoring.

5 days ago

Journal

ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SDC4 (Syndecan 4)

ROS1 fusion • ROS1 positive

Xalkori (crizotinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib)

UNLOCK ASP3082: Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (clinicaltrials.gov)

P2, N=60, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting

6 days ago

Enrollment open

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

KRAS mutation • EGFR mutation • BRAF mutation • KRAS G12D • RET fusion • RET mutation • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion

setidegrasib (ASP3082)

Next generation sequencing guided treatment of ALK tyrosine kinase inhibitor induced long survival in lung squamous cell carcinoma harboring ROS1 gene fusions: a case report and literature review. (PubMed, Front Med (Lausanne))

Peripheral monocyte profiling of the patient post-Repotrectinib and localized radiotherapy showed 75% CD8+/CD3 + T cells, 14.2% CD4+/CD3 + T cells, 3.95% regulatory T cells (Tregs), and 38% PD-1 + CD3 + T cells...Furthermore, we also provide a comprehensive review of recent clinical advancements in ALK/ROS1-TKI for NSCLC, including mechanistic insights into TKI resistance development. This case underscores the therapeutic potential of molecular-targeted agents in LUSC and highlights the essential role of NGS-guided precision oncology.

9 days ago

Journal • Next-generation sequencing • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)

PD-L1 expression • EGFR mutation • ALK mutation • ROS1 fusion • ROS1 rearrangement

Augtyro (repotrectinib)

10d

LUNG-MAP Sub-Study: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (clinicaltrials.gov)

P2, N=124, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

10 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive

FoundationOne® CDx

Retevmo (selpercatinib)

13d

P2, N=60, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris

13 days ago

New P2 trial

KRAS mutation • EGFR mutation • BRAF mutation • KRAS G12D • RET fusion • RET mutation • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion

setidegrasib (ASP3082)

16d

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance (clinicaltrials.gov)

P=N/A, N=40, Enrolling by invitation, Chang Gung Memorial Hospital | Not yet recruiting --> Enrolling by invitation

16 days ago

Enrollment open

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • BRAF V600 • HER-2 mutation • RET fusion • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • MET mutation • KRAS G12

19d

Genomic landscape and homologous recombination deficiency in malignant germ cell tumors reveals sex-specific therapeutic opportunities. (PubMed, J Pathol)

This study underscores the presence of sex-specific therapeutic vulnerabilities in GCTs, which warrant further exploration in larger cohorts.

19 days ago

Journal • BRCA Biomarker • PARP Biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA2 (Breast cancer 2, early onset) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRD (Homologous Recombination Deficiency) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)

TP53 mutation • MET amplification • HRD • ROS1 fusion

20d

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=32, Not yet recruiting, University of Washington | Initiation date: Mar 2026 --> Jun 2026

20 days ago

Trial initiation date • Checkpoint inhibition

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CXCL8 (Chemokine (C-X-C motif) ligand 8)

RET fusion • ALK fusion • ROS1 fusion

SX-682 • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

21d

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (clinicaltrials.gov)

P1, N=15, Recruiting, Nationwide Children's Hospital | Active, not recruiting --> Recruiting

21 days ago

Enrollment open

ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 fusion

carboplatin • Lorbrena (lorlatinib) • cyclophosphamide

22d

Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies. (PubMed, J Thorac Dis)

There are several challenges including the lack of randomized perioperative trials, heterogeneity in pathological response assessment, and uncertainty regarding the reliability of surrogate endpoints. With the increasing integration of next-generation sequencing into the standard diagnostic workup of early-stage NSCLC, biomarker-directed perioperative strategies supported by prospective clinical trials enriched for specific genotypes are critical to achieving sustained clinical outcomes in these patient subgroups with rare targetable alterations.

22 days ago

Review • Journal • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • EGFR exon 20 insertion • MET exon 14 mutation • ROS1 fusion • KRAS G12 • EGFR exon 20 mutation • NTRK fusion

22d

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)

P1/2, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Jun 2027

22 days ago

Enrollment open • Trial initiation date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • EGFR mutation • HER-2 negative • BRAF V600 • ALK rearrangement • ALK fusion • ROS1 fusion • ROS1 rearrangement • NTRK fusion

DCSZ11